Compare Amcor PLC (AMCR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amcor PLC vs BIO-TECHNE Corp — how do they compare? Amcor PLC trades at $46.87 (market cap $21.78B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Amcor PLC is the larger of the two by market cap, and Amcor PLC pays the higher dividend (5.52%). Which is the better fit depends on your goals.
| AMCR | TECH | |
|---|---|---|
Market Cap | $21.78B | $11.24B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $72.29 |
52-Week Low | $36.69 | $43.31 |
Enterprise Value | $36.90B | $11.32B |
Dividend Yield | 5.52% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $47.86, up 1.7% today, near the consensus price target of $47.00. The stock shows bullish technical signals from moving averages, with RSI indicating mild overbought conditions. Recent quarters saw earnings beats, with Q2 2026 EPS expected at $1.19. Revenue grew to $15.01B in 2025, though net income margin declined to 3.06%. The company expanded its packaging facility in China and partnered with Kelpi for sustainable solutions, signaling growth initiatives.
Outlook is cautiously optimistic with analyst consensus at Buy (64%), but risks include margin pressure and high P/E of 38.44. Investment appeal hinges on earnings delivery and cost management amid competitive and macroeconomic headwinds.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
